Par Pharmaceutical

Type: Company
Name: Par Pharmaceutical
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Intellipharmaceutics Turns To Profit In Q1 - Quick Facts

Intellipharmaceutics International Inc. (IPCI: Quote, I.TO), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported net income for ... [Published RTTNews.com - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Par Pharmaceutical Names Terrance J. Coughlin Chief Operating Officer

By a News Reporter-Staff News Editor at Pharma Business Week Par Pharmaceutical Companies, Inc. announced that Terrance J. Coughlin has been named chief operating officer. In this capacity, Mr. Coughlin will be responsible for Par's global manufacturing ... [Published Pharmacy Choice - Apr 14 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

DIGOXIN Tablet [Par Pharmaceutical, Inc]

First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

Par Pharmaceutical Begins Shipment of Potassium Chloride Extended-Release Capsules

/PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for potassium chloride extended-release (ER) capsules, USP, in 600 ... [Published Yahoo! Finance - Apr 07 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Corium pulls off a $52M IPO to fund its needle-free pipeline

Menlo Park, CA's Corium International ($CORI) pocketed $52 million in an IPO to match established drugs with convenient delivery platforms, scoring the quarter's first Wall Street debut as the industry hopes an early-year bull market can survive into ... [Published FierceBiotech - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 4 reports

Par Pharmaceutical Names New Chief Operating Officer

Par Pharmaceutical Companies today announced that Terrance J. Coughlin has been named chief operating officer. In this capacity, Mr. Coughlin will be responsible for Par's global manufacturing ... ... [Published Big News Network - Apr 02 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

US wants at least $1 billion from drugmakers who delay generics

Deborah Feinstein, director of the US Federal Trade Commission's Bureau of Competition suggested that the agency is seeking a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of generic medicines, as reported ... [Published FirstWord Pharma - Mar 28 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Corium poised for $66M IPO for wearable drug-delivery devices

by California-based Corium unveils plans for a $66 million initial public offering for its transdermal drug delivery technology.Drug-delivery devices maker Corium could raise up to $66 million through an initial public offering, the company announced ... [Published MassDevice - Mar 24 2014]
First reported Mar 22 2014 - Updated Mar 22 2014 - 1 reports

CIPROFLOXACIN EXTENDED-RELEASE (Ciprofloxacin) Tablet, Film Coated, Extended Release [Par Pharmaceutical, Inc.]

First reported Mar 22 2014 - Updated Mar 22 2014 - 1 reports

MEGACE ES (Megesterol Acetate) Suspension [Par Pharmaceutical, Inc]

First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Hyperion faces generic challenge to year-old rare disease drug

A year after hitting the market with a rare disease treatment, Hyperion Therapeutics Inc. is facing a challenge from a generic drug maker.The Brisbane drug developer (NASDAQ: HPTX) said Par Pharmaceutical Inc. (NYSE: PRX) has filed an abbreviated new ... [Published San Francisco Business Times - Mar 19 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 2 reports

Par Pharmaceutical Announces Fourth Quarter and Full Year 2013 Conference Call

/PRNewswire/ -- Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, March 20, 2014 at 10:00 a.m. EDT to review its results of operations for the fourth quarter and full year ended December 31 , 2013.  Par ... [Published Asian Hospital & Healthcare Management - Mar 18 2014]

Quotes

...and capable senior manager with a proven track record of success," said Paul V Campanelli, chief executive officer of Par Pharmaceutical Companies. "Terry's more than 25 years experience in the pharmaceutical industry extends from API to finished dosage, and from R&D to sales and marketing. He has managed businesses, including manufacturing facilities, in the U S and abroad. Terry's breadth of experience will serve Par well and I am excited to welcome him to our company."
...The Israeli drugmaker noted that it "believes it is first-to-file and thus far is the only company to receive an approval."
Infringement of certain of U S Patent Nos. 5,288,726 ( "Tetrahydrothienopyridine Derivatives, Furo and Pyrrolo Analogs Thereof and Their Preparation and Uses for Inhibiting Blood Platelet Aggregation" issued February 22, 1994), 8,404,703 ("Medicinal Compositions Containing Aspirin," issued March 26, 2013) and 8,569,325 ("Method of Treatment with C...
In a filing, the company said, "On March 10, Hyperion Therapeutics (HPTX) disclosed that it had become aware that the FDA on March 6, posted on its website that FDA’s Office of Generic Drugs had received an Abbreviated New Drug Application, ANDA, containing a Paragraph IV patent certification with respect to RAVICTI, glycerol phenylbutyrate, oral liquid on November 19, but that the company had not received notification of the Paragraph IV certification with respect to this filing. On March 17, the company received notification of the Paragraph IV certification from Par Pharmaceutical (PRX) advising the company that it had filed an ANDA with the FDA for a generic version of 1.1 gm/ml RAVICTI oral liquid. The Paragraph IV certification alleges that the company’s U S Patent No. 8,404,215, titled “Methods of therapeutic monitoring of nitrogen scavenging drugs,” which expires in March 2032, and U S Patent No. 8,642,012, titled “Methods of treatment using ammonia scavenging drugs,” which expires in September 2030, are invalid and/or will not be infringed by Par’s manufacture, use or sale of the product for which the ANDA was submitted. Par did not challenge the validity, enforceablility, or infringement of the company’s U S Patent No. 5,968,979, titled “Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders,” which expires in February 2015. The company intends to vigorously enforce its intellectual property rights relating to RAVICTI. As noted in the Initial Form 8-K, the Paragraph IV certification does not challenge or affect RAVICTI’s orphan drug exclusivity, which extends to February 2020."

More Content

All (52) | News (39) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (1) | Press Releases (3)
sort by: Date | Relevance
Intellipharmaceutics Turns To Profit In Q1 - Qu... [Published RTTNews.com - Apr 14 2014]
Par Pharmaceutical Names Terrance J. Coughlin C... [Published Pharmacy Choice - Apr 14 2014]
Intellipharmaceutics Announces First Quarter 20... [Published Virtual Strategy Magazine - Apr 14 2014]
Intellipharmaceutics Announces First Quarter 20... [Published Benzinga.com - Apr 14 2014]
DIGOXIN Tablet [Par Pharmaceutical, Inc] [Published DailyMed Drug Label Updates for the last seven ... - Apr 08 2014]
Teva gains first FDA approval for generic versi... [Published FirstWord Pharma - Apr 08 2014]
TWi Pharmaceuticals shares surge after US approval [Published Taipei Times Online - Apr 07 2014]
Par Pharmaceutical Begins Shipment of Potassium... [Published Yahoo! Finance - Apr 07 2014]
Par Pharmaceutical Begins Shipment of Potassium... [Published PR Newswire: Health - Apr 07 2014]
Novartis gets new head of Japanese business ami... [Published FierceBiotech - Apr 04 2014]
Corium pulls off a $52M IPO to fund its needle-... [Published FierceBiotech - Apr 03 2014]
Global Healthcare Private Equity Report 2014 [Published Bain & Company - Apr 03 2014]
Par Pharmaceutical Names New Chief Operating Of... [Published Big News Network - Apr 02 2014]
Par Pharmaceutical appoints Terrance Coughlin a... [Published Pharma Letter - Apr 01 2014]
Par Pharmaceutical Names Terrance J. Coughlin C... [Published TickerTech.com - Apr 01 2014]
Par Pharmaceutical Names Terrance J. Coughlin C... [Published PR Newswire: General Business - Apr 01 2014]
Busy IPO Calendar Cheatsheet [Published Seeking Alpha - Apr 01 2014]
US wants at least $1 billion from drugmakers wh... [Published FirstWord Pharma - Mar 28 2014]
Corium poised for $66M IPO for wearable drug-de... [Published MassDevice - Mar 24 2014]
Global Generic Drugs Market 2014-2018: Branded ... [Published Individual.com - Mar 24 2014]
CIPROFLOXACIN EXTENDED-RELEASE (Ciprofloxacin) ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
MEGACE ES (Megesterol Acetate) Suspension [Par ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
Lautus Pharma Announces Acquisition and Re-laun... [Published Business Wire - Mar 20 2014]
Hyperion faces generic challenge to year-old ra... [Published San Francisco Business Times - Mar 19 2014]
Court Report [Published JD Supra - Mar 18 2014]
Hyperion says Par filed ANDA with FDA for gener... [Published Yahoo! Finance - Mar 18 2014]
IntelGenx Technologies : 2014-03-11 IntelGenx R... [Published 4 Traders - Mar 18 2014]
Par Pharmaceutical Announces Fourth Quarter and... [Published Asian Hospital & Healthcare Management - Mar 18 2014]
Par Pharmaceutical to Host 4Q and Full Year 201... [Published Individual.com - Mar 18 2014]
Snowball Effect: The Incidence of Premature Par... [Published FDA Law Blog - Mar 17 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DIGOXIN Tablet [Par Pharmaceutical, Inc] [Published DailyMed Drug Label Updates for the last seven ... - Apr 08 2014]
Updated Date: Apr 8, 2014 EST ...
Par Pharmaceutical Begins Shipment of Potassium... [Published PR Newswire: Health - Apr 07 2014]
WOODCLIFF LAKE, N.J., April 7, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for potassium chloride extended-release ...
Par Pharmaceutical Names Terrance J. Coughlin C... [Published PR Newswire: General Business - Apr 01 2014]
WOODCLIFF LAKE, N.J., April 1, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that Terrance J. Coughlin has been named chief operating officer.  In this capacity, Mr. Coughlin will be responsible for Par's global manufacturing ...
CIPROFLOXACIN EXTENDED-RELEASE (Ciprofloxacin) ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
Updated Date: Mar 21, 2014 EST ...
MEGACE ES (Megesterol Acetate) Suspension [Par ... [Published DailyMed Drug Label Updates for the last seven ... - Mar 22 2014]
Updated Date: Mar 19, 2014 EST ...
1 2

Press Releases

sort by: Date | Relevance
Par Pharmaceutical to Acquire JHP Pharmaceuticals [Published Financial Services - Jan 21 2014]
Par Pharmaceutical Begins Shipment of Generic L... [Published Financial Services - Jan 16 2014]
IntelGenx Announces Additional Development and ... [Published GlobeNewswire: Acquisitions News - Jan 13 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.